Ligand Pharmaceuticals Incorporated Stock Total Asset
| LGND Stock | USD 122.70 1.23 1.01% |
Ligand Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Ligand Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ligand Stock. The fundamental analysis module provides a way to measure Ligand Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ligand Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 787.2 M | 451.3 M | |
| Intangibles To Total Assets | 0.60 | 0.32 |
Ligand | Total Asset |
Ligand Pharmaceuticals Incorporated Company Total Asset Analysis
Ligand Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Ligand Pharmaceuticals Total Asset | 787.22 M |
Most of Ligand Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ligand Pharmaceuticals Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ligand Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Ligand Pharmaceuticals is extremely important. It helps to project a fair market value of Ligand Stock properly, considering its historical fundamentals such as Total Asset. Since Ligand Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ligand Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ligand Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Ligand Total Asset Historical Pattern
Today, most investors in Ligand Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ligand Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ligand Pharmaceuticals total asset as a starting point in their analysis.
Ligand Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Ligand Total Assets
Total Assets |
|
Based on the latest financial disclosure, Ligand Pharmaceuticals Incorporated has a Total Asset of 787.22 M. This is 89.53% lower than that of the Biotechnology sector and 60.16% lower than that of the Health Care industry. The total asset for all United States stocks is 97.33% higher than that of the company.
Ligand Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ligand Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ligand Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ligand Pharmaceuticals by comparing valuation metrics of similar companies.Ligand Pharmaceuticals is currently under evaluation in total asset category among its peers.
Ligand Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ligand Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ligand Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Ligand Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Ligand Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ligand Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ligand Pharmaceuticals' value.| Shares | Loomis, Sayles & Company Lp | 2024-09-30 | 372.8 K | Rice Hall James & Associates, Llc | 2024-09-30 | 312.9 K | Ashford Capital Management Inc | 2024-09-30 | 310.4 K | Impax Asset Management Group Plc | 2024-09-30 | 280.2 K | Deutsche Bank Ag | 2024-06-30 | 270.2 K | Northern Trust Corp | 2024-09-30 | 262.8 K | Abrdn Plc | 2024-09-30 | 249.3 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 237 K | William Blair Investment Management, Llc | 2024-09-30 | 205.7 K | Blackrock Inc | 2024-06-30 | 2.9 M | Vanguard Group Inc | 2024-09-30 | 2 M |
Ligand Fundamentals
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.013 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 2.08 B | ||||
| Shares Outstanding | 18.9 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 99.91 % | ||||
| Number Of Shares Shorted | 831.45 K | ||||
| Price To Earning | 29.74 X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 15.19 X | ||||
| Revenue | 131.31 M | ||||
| Gross Profit | 107.34 M | ||||
| EBITDA | 101.73 M | ||||
| Net Income | 52.15 M | ||||
| Cash And Equivalents | 147.94 M | ||||
| Cash Per Share | 8.76 X | ||||
| Total Debt | 6.17 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | 44.84 X | ||||
| Cash Flow From Operations | 49.58 M | ||||
| Short Ratio | 6.31 X | ||||
| Earnings Per Share | 2.49 X | ||||
| Price To Earnings To Growth | 1.53 X | ||||
| Target Price | 140.25 | ||||
| Number Of Employees | 58 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 2.32 B | ||||
| Total Asset | 787.22 M | ||||
| Retained Earnings | 503.02 M | ||||
| Working Capital | 220.65 M | ||||
| Current Asset | 214.71 M | ||||
| Current Liabilities | 222.82 M | ||||
| Net Asset | 787.22 M |
About Ligand Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ligand Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out Ligand Pharmaceuticals Piotroski F Score and Ligand Pharmaceuticals Altman Z Score analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.